Emerging biotech companies are a significant and burgeoning sector of the pharmaceutical development market. These companies may require unique and specialized expertise to guide them through asset development. There are a multitude of considerations when evaluating an asset for development, including the vision for the asset, development and continuum capabilities, and global versus local development.
Download our latest whitepaper to learn:
- How to navigate the complexities of asset development
- Overall considerations emerging biotech companies can be discussing with development partners
- What makes a successful partner who can assist a small biotech company with necessary development strategies
This is the first in a series of white papers that will help outline considerations for asset development. Lead the pack in all steps of the development process with this guide.
Chemistry, Manufacturing, and Controls (CMC) in Drug Development and Life Cycle Management
This white paper provides biotech companies an overview of the considerations for Chemistry, Manufacturing and Controls (CMC) in asset development.…
Are We There Yet? - Beyond the Target Product Profile
In the previous blog, we looked at the concept of the Target Product Profile (TPP). At one level, the TPP can be thought of as a document that sets…
Building Long-Lasting Partnerships – A Biotech Success Story
PRA has experience partnering with small biotech firms, and we understand that they require a different approach than larger pharmaceutical…